New treatment to reverse opioid overdose
Novel Therapeutic Agents to Reverse Opioid Overdose
This study is testing a new injection called CS-1103 that aims to quickly reverse the effects of fentanyl overdoses, offering a potentially better option than the usual treatment, naloxone, for people who might need help in an emergency.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Clear Scientific, LLC NIH-funded |
| Lab location | 1 site (Cambridge, United States) |
| Project ID | NIH-10492707 on NIH RePORTER |
What this research studies
This research focuses on developing a new medication, CS-1103, that can quickly reverse the effects of fentanyl and its analogues, which are increasingly responsible for overdose deaths. Unlike naloxone, which is commonly used but less effective against fentanyl, CS-1103 works by binding to the drug in the bloodstream and helping to eliminate it from the body more rapidly. The goal is to create a formulation that can be administered via injection in emergency situations, providing a potentially life-saving option for individuals experiencing an opioid overdose. The research aims to optimize the dosage and formulation for effective use in real-world scenarios.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals at risk of opioid overdose, particularly those using fentanyl or its analogues.
Not a fit: Patients who do not use opioids or are not at risk of overdose may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment option for reversing opioid overdoses, potentially saving countless lives.
How similar studies have performed: While naloxone has been widely used, this approach with CS-1103 represents a novel method that has not yet been tested in clinical settings.
Where this research is happening
Cambridge, United States
- Clear Scientific, LLC — Cambridge, United States (Active)
Researchers
- Principal investigator: Li, Xinhua — Clear Scientific, LLC
- Study coordinator: Li, Xinhua
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.